Tang (2018b,a) derived the exact power formulae for t tests and analysis of covariance (ANCOVA) in superiority, noninferiority and equivalence trials. The power calculation in equivalence trials can be simplified by using Owen's Q function, which is available in standard statistical software. We extend the exact power determination method for ANCOVA to unstratified and stratified multi-arm randomized trials. The method is applied to the design of multi-arm trials and gold standard noninferiority trials
1 Introduction Tang (2018a,b) obtained the exact power formulae for some commonly used t tests in superiority, noninferiority (NI) and equivalence trials. The power determination for the analysis of covariance (ANCOVA) and t-test with unequal variances in equivalence trials involves two-dimensional numerical integration. We show that the calculation can be simplified by using Owen's Q function, which is available in standard statistical software packages (e.g. SAS and R PowerTOST ). We extend the method for AN-COVA to unstratified and stratified multi-arm randomized trials, and apply it to the power determination for multi-arm trials and gold standard NI trials (Pigeot et al., 2003) .
We use the same notations as Tang (2018a,b) . Let t(f, λ) denote the t distribution with f degrees of freedom and noncentrality parameter λ, t f,p the pth percentile of the central t distribution, Φ(·) the cumulative distribution function (CDF) of N (0, 1),
2 )dx Owen's Q function. Let n g be the number of subjects in group g, n the total size, M 0 the superiority (M 0 = 0) or NI margin, and (M l , M u ) the lower and upper equivalence margins. Without loss of generality, we assume high scores indicate better health.
Two sample t tests
Let (τ , n −1V ) be the estimated effect and variance with true values (τ 1 , n −1 V ) in a test based on the t distribution.
f . In superiority and NI trials, we reject the null hypothesis when
By the change of variable x = √ f ξ, the exact power equation (26) of Tang (2018b) can be rearranged in terms of Owen's Q function as
In the t test with unequal variances [i.e. y 0i
iid ∼ N (µ 1 , σ 2 1 )], the power of the superiority and NI trial is obtained from the fact (Moser et al., 1989; Tang, 2018b) 
The exact equivalence power (equation (A3) of Tang (2018b)) can be reexpressed as
. Please see Tang (2018b) for numerical examples.
3 ANCOVA Tang (2018a,b) derived the exact power formulae for ANCOVA analysis of two-arm trials. Below we present more general results for unstratified or stratified multi-arm randomized trials. Suppose subjects are randomized to K * = K + 1 treatment groups (g = 0, . . . , K) within each of h strata. In an unstratified trial, we set h = 1. Subjects in treatment group g are modeled by y gi = µ g +z gi 1 α 1 +. . .+z gi r−1 α r−1 +x ′ gi β+ε gi = η+δ g +z gi 1 α 1 +. . .+z gi r−1 α r−1 +x ′ gi β+ε gi where z gi k (k = 1, . . . , r − 1) is the indicator variable for the pre-stratification factors, µ g is the effect for treatment group g, x gi is the q × 1 vector of baseline covariates, ε gi ∼ N (0, σ 2 ), η = µ 0 and δ g = µ g − µ 0 . In general, r equals the number of strata h. In trials with multiple stratification factors, r < h if there is no interaction between some stratification factors. By the same arguments as the proof of equation (15) in Tang (2018a) , we obtain the variance for the linear contrast with coefficients
where K g=0 l g = 0,z g is the mean of z gi = (z gi 1 , . . . , z gi r−1 ) ′ in group g, S zz = K g=0 ng i=1 (z gi −z g ) ⊗2 ,Υ is a function of the covariate x gi 's, and V l = g l 2 g /n g + ( g l gzg ) ′ S −1 zz ( g l gzg ). In a two arm trial (Tang, 2018a) , V l = h s=1 n s1 n s0 n s1 +n s0 −1 if there is no restriction on the stratum effect (i.e. r = h), where n sg is the number of subjects in stratum s, treatment group g. A constant treatment allocation ratio is commonly used in practice. Thenz 0 = . . . =z K and V l = g l 2 g /n g . Let τ 1 = g l g µ g , f = n − q − r − K, and f 2 = f + 1. When x gi 's are normally distributed, Υ ∼ F (q, f 2 ) and the exact power for the superior or NI test is
Formula (4) also provides very accurate power estimate for nonnormal covariates (Tang, 2018b) . In equivalence trials, the exact power is Tang (2018b) , equation (30) of Tang (2018a)) for two arm trials are equivalent to equation (5) at K = 1.
The power formulae (2), (3), (4) and (5) are of the form ∞ 0 P c (x)dF f 1 ,f 2 (x), and can be calculated as
Below we give three hypothetical examples. Sample R code is provided in the Supplementary Material. In each example, the simulated (SIM) power is evaluated based on 4, 000, 000 simulated datasets. There is more than 95% chance that the SIM power lies within 0.05% of the true power. In example 1, we perform the power calculation for a superiority trial. Subjects are randomized equally into K * = 3 groups (K = 2 experimental, or control treatment) stratified by gender (z gi 1 = 1 for male, 0 for female) and age (z gi 2 = 1 if old, 0 otherwise). There are 6 subjects per treatment group per stratum (n 0 = n 1 = n 2 = 24, n = 72). There is no interaction between age and gender (r = 3, h = 4), and the outcome is normally distributed as
where (µ 0 , µ 1 , µ 2 ) = (0, 0.6, 0.9) and x gi ∼ N (0.2z gi 1 + 0.4z gi 2 , 1). We compare each experimental treatment versus control treatment at the Bonferroni-adjusted one tailed significance level of α/2 = 0.0125. The exact power by formula (4) is 78.63% and 41.39%, and the SIM power is 78.62% and 41.39% respectively for the two tests.
Example 2 has similar setup to example 1 except that (µ 0 , µ 1 , µ 2 ) = (0, 0.05, 0.1) and the sample size is 30 per group per stratum (n 0 = n 1 = n 2 = 120, n = 360).
The aim is to establish the equivalence of each experimental treatment versus control treatment at α/2 = 0.0125. The margin is (M l , M u ) = (−0.5, 0.5). The exact power by formula (5) is 79.14% and 86.72% respectively for the two tests, while the SIM power is 79.14% and 86.71%.
In example 3, we design a three-arm "gold standard" NI trial (Pigeot et al., 2003) .
It consists of placebo (g = 0), an active control treatment (g = 1) and an experimental treatment (g = 2). The set up is similar to example 1 except that (µ 0 , µ 1 , µ 2 ) = (0, 1, 1.1), and the sample size is 10 per group per stratum (n 0 = n 1 = n 2 = 40, n = 120). Two tests are conducted at the one-sided significance level of α/2 = 0.025. Test 1 evaluates the superiority of treatment 1 over placebo. The power for this test (exact P 1 = 99.29%, SIM 99.28%) is very close to 1. In test 2, we assess the noninferiority of treatment 2 to treatment 1 by demonstrating that treatment 2 preserves at least 50% of the efficacy of treatment 1 compared to placebo (i.e. µ 2 −µ 0 µ 1 −µ 0 > 50% or µ 2 − 0.5µ 1 − 0.5µ 0 > 0). The exact power of test 2 is P 2 = 86.41% (SIM power 86.41%). The noninferiority is claimed only if both tests are significant (Pigeot et al., 2003) , and the overall power is at least P 1 + P 2 − 1 = 85.70% while the simulated power is 85.80%.
